Brainstorm Cell Therapeutics, Inc. operates as a biotechnology company, which develops and commercializes adult stem cell therapeutic products. It focuses on utilizing the patients own bone marrow stem cells to generate neuron-like cells that may provide an effective treatment initially for amyotrophic lateral sclerosis, Parkinson's disease, multiple sclerosis and spinal cord injury. Read More The company was founded on September 22, 2000 and is headquartered in New York, NJ. The listed name for BCLI is Brainstorm Cell Therapeutics Inc. Common Stock.